Does a GLP-1 Affect Blood Pressure? Lower, Higher, or Both — The Evidence

The honest answer to “does a GLP-1 affect my blood pressure” is: yes, in two directions. On average, GLP-1 receptor agonists lower systolic blood pressure by about 5-7 mmHg and diastolic by 2-3 mmHg in the obesity registration trials, an effect partly explained by weight loss and partly direct vascular and renal mechanisms. They also raise resting heart rate by about 2-4 bpm in most patients, an effect that is in the FDA labels and worth knowing about. The 2023 SELECT cardiovascular outcomes trial showed that semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% in patients with obesity and pre-existing CV disease. This article walks through the trial-by-trial blood pressure evidence and the practical implications for patients on antihypertensive medications.

The trial-reported blood pressure effects

Blood pressure was a pre-specified secondary endpoint in every major GLP-1 weight management trial. The published results at the maintenance dose:

STEP-1 (semaglutide 2.4 mg)^[1]

• Mean systolic BP change: −6.2 mmHg on semaglutide vs −1.1 mmHg on placebo at week 68
• Mean diastolic BP change: −2.8 mmHg on semaglutide vs −0.4 mmHg on placebo
• Mean resting heart rate increase: +3 bpm on semaglutide

SURMOUNT-1 (tirzepatide 15 mg)^[2]

• Mean systolic BP change: −7.2 mmHg on tirzepatide 15 mg vs −1.0 mmHg on placebo at week 72
• Mean diastolic BP change: −4.8 mmHg on tirzepatide vs −0.8 mmHg placebo
• Mean resting heart rate increase: +2-4 bpm across the tirzepatide doses

SELECT (semaglutide 2.4 mg cardiovascular outcomes)^[3]

SELECT was the largest cardiovascular outcomes trial of a GLP-1 in non-diabetic patients with obesity. n=17,604, mean follow-up 39.8 months, mean BMI 33. Headline result:20% reduction in major adverse cardiovascular events (cardiovascular death, non-fatal MI, non-fatal stroke) in the semaglutide arm vs placebo. The BP component contributed: at year 2, the semaglutide arm had a sustained 4.3 mmHg lower systolic BP than placebo, an effect that contributed to but did not fully explain the CV benefit.

LEADER and SUSTAIN-6 (older liraglutide and semaglutide diabetes trials)^[4][8]

Both the older liraglutide (LEADER) and semaglutide (SUSTAIN-6) cardiovascular outcomes trials in type 2 diabetes also showed modest BP reductions (~1-2 mmHg) and heart rate increases (~3 bpm) at lower doses than the current obesity-management drugs.

The Sun 2015 meta-analysis

A network meta-analysis by Sun and colleagues^[5] pooled blood pressure data across 33 randomized trials of GLP-1 receptor agonists in type 2 diabetes (n=12,469 patients). The pooled effect: a mean systolic BP reduction of 2.2 mmHg vs placebo across older GLP-1s at lower doses. At the higher doses now used for weight management (Wegovy 2.4 mg, Zepbound 15 mg), the BP effect is roughly 2-3 times larger.

Why GLP-1s lower blood pressure

Three mechanisms contribute:

1. Weight loss. Each kilogram of body weight lost is associated with approximately 1 mmHg reduction in systolic BP in non-pharmacologic interventions. A patient losing 15% body weight on a GLP-1 (mean STEP-1 result) loses about 14-15 kg, which predicts a ~10-15 mmHg systolic reduction from weight alone.
2. Natriuresis (sodium excretion). GLP-1 receptors are expressed in the proximal tubule of the kidney and activation increases sodium excretion, which reduces extracellular volume and blood pressure independent of weight loss.
3. Direct vascular effects. GLP-1 receptors are expressed on vascular endothelium and smooth muscle. Activation produces vasodilation via nitric oxide pathways, contributing further to the BP reduction.

The net result is a BP reduction that exceeds what you would predict from the weight loss alone — meaning some of the effect is genuinely pharmacologic, not just a secondary consequence of getting smaller.

The heart rate increase — the labeled adverse effect

The other side of the cardiovascular story is that GLP-1s increase resting heart rate by about 2-4 bpm in most patients^[6][7]. This is in Section 5.5 of the Wegovy and Zepbound labels and is consistently seen across the GLP-1 class. The mechanism is thought to involve GLP-1 receptor activation in the sinoatrial node and possibly increased sympathetic tone.

The clinical significance of a 2-4 bpm increase is small for most patients. It is not clinically meaningful in someone with a baseline heart rate of 70 bpm. It can be more concerning in patients with:

• Pre-existing tachyarrhythmias (atrial fibrillation, supraventricular tachycardia)
• Heart failure with preserved ejection fraction (HFpEF)
• Long QT syndrome or other repolarization abnormalities
• Untreated thyroid disease

Practical implications for patients on antihypertensive medications

If you are on blood pressure medication when you start a GLP-1, the BP-lowering effect can stack with your existing therapy in a few weeks to months and you may need to reduce or stop antihypertensive doses. Patient experience and clinical guidance:

• Monitor blood pressure at home weekly during the first 3-6 months of GLP-1 therapy. A simple home cuff is enough.
• Symptomatic hypotension — dizziness on standing, lightheadedness, fainting — is a sign that your blood pressure is now too low for your current antihypertensive dose. Call your prescriber.
• Diuretics first to deprescribe. The natriuretic effect of GLP-1s overlaps with thiazide and loop diuretics; many patients can taper diuretics first when their BP starts running low.
• Beta blockers may need to be reduced or continued depending on the indication. Patients on a beta blocker for tachycardia or atrial fibrillation should keep it; patients on a beta blocker only for hypertension may be able to taper.
• ACE inhibitors and ARBs are typically the last to deprescribe because they have non-BP benefits (renal protection in diabetes, post-MI remodeling).

The deprescribing decision should always be made by the clinician managing your blood pressure, not unilaterally. See our GLP-1 drug interaction checker for the antihypertensive interaction entries.

What if your blood pressure goes UP on a GLP-1?

Population means hide individual variation. A small fraction of patients see modest BP increases on a GLP-1 despite the average effect being downward. Reasons this can happen include:

• The heart rate increase can produce a small reflex BP rise in some patients
• White-coat hypertension stress from frequent prescriber visits during titration
• Stopping a previously tolerated antihypertensive when starting GLP-1, anticipating a drop that didn't materialize as quickly
• Independent BP rise unrelated to GLP-1 — pre-existing hypertension that's progressing on its own trajectory
• Drug interaction with sympathomimetics (e.g., decongestants like pseudoephedrine, ADHD stimulants, or phentermine — see our phentermine + GLP-1 article)

If your home BP readings are trending up despite weight loss on a GLP-1, check the simple things first (cuff technique, time of day, recent caffeine, recent decongestant use) and then call your prescriber.

The cardiovascular outcomes case (SELECT)^[3]

The SELECT trial is the strongest evidence that the BP reduction translates to real cardiovascular benefit. In a population of 17,604 adults with obesity (BMI ≥27) and pre-existing cardiovascular disease but no diabetes, semaglutide 2.4 mg vs placebo over a mean 39.8 months:

• 20% reduction in the primary composite (cardiovascular death, non-fatal MI, non-fatal stroke): HR 0.80, 95% CI 0.72-0.90
• 15% reduction in cardiovascular death
• 19% reduction in heart failure hospitalization
• The BP component (4.3 mmHg lower systolic at year 2) contributed to but did not fully explain the benefit

On the strength of SELECT, the FDA added a labeled cardiovascular benefit indication to Wegovy in 2024 — the first weight-loss drug with formal cardiovascular outcome labeling. Zepbound and Foundayo do not yet have this indication; their cardiovascular outcome trials are either still running (SURPASS-CVOT for tirzepatide) or haven't been initiated.

Bottom line

• GLP-1 receptor agonists lower systolic blood pressure by about 5-7 mmHg and diastolic by 2-3 mmHg on average at the maintenance dose.
• The mechanism is part weight loss, part natriuresis, part direct vascular effect.
• The same drugs raise resting heart rate by about 2-4 bpm — in the FDA labels as a Section 5.5 warning, but clinically minor for most patients.
• Patients on antihypertensive medication should monitor BP at home weekly during the first 3-6 months and coordinate dose reductions with their prescriber.
• The 2023 SELECT trial showed semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% in patients with obesity and pre-existing CV disease — leading to a formal cardiovascular benefit indication on the Wegovy label.
• A small number of patients see BP increases despite the average effect being downward; check simple causes first and call your prescriber.

Related research and tools

• SELECT trial: cardiovascular benefits in non-diabetics — the full SELECT review
• FLOW trial: semaglutide in kidney disease — the renal outcomes companion
• STEP-HFpEF: semaglutide in heart failure
• 17 GLP-1 side effect questions answered
• Can you take phentermine with a GLP-1? — the cardiovascular load argument against combination
• GLP-1 drug interaction checker
• GLP-1 BMI calculator

Important disclaimer. This article is educational and does not constitute medical advice. Blood pressure management decisions, including starting, stopping, or adjusting any antihypertensive medication, should always be made with the prescribing clinician. If you experience symptomatic hypotension, severe headache, unusual chest discomfort, or other cardiovascular symptoms on a GLP-1, contact your prescriber promptly.